View Older Stories View More Recent Stories

Jul 30, 2025 06:40AM Ideaya Biosciences (IDYA) PT Lowered to $43 at Mizuho
Jul 22, 2025 01:01PM IDEAYA and Hengrui to present lung cancer drug data at conference
Jul 22, 2025 05:43AM TD Cowen Starts Ideaya Biosciences (IDYA) at Buy
Jul 10, 2025 06:29AM Goldman Sachs Resumes Ideaya Biosciences (IDYA) at Neutral
Jul 9, 2025 10:35AM Ideaya Biosciences (IDYA) PT Lowered to $30 at RBC Capital
Jun 26, 2025 06:23AM Wells Fargo Starts Ideaya Biosciences (IDYA) at Overweight
May 6, 2025 06:33AM IDEAYA Biosciences (IDYA) Misses Q1 EPS by 14c
May 6, 2025 06:01AM IDEAYA Biosciences (IDYA) Announces FDA IND-Clearance for IDE849
Apr 14, 2025 06:00AM IDEAYA Biosciences (IDYA) Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib
Mar 31, 2025 06:29AM IDEAYA Biosciences (IDYA) Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Feb 13, 2025 06:27AM IDEAYA Biosciences (IDYA) Misses Q4 EPS by 149c
Feb 13, 2025 06:04AM IDEAYA Biosciences (IDYA) Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397
Feb 10, 2025 06:02AM IDEAYA Biosciences (IDYA) Appoints Joshua Bleharski as CFO
Jan 21, 2025 06:24AM BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel
Dec 30, 2024 04:19AM BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025
Dec 17, 2024 08:17AM RBC Capital on Ideaya Biosciences (IDYA): 'R&D Day Underscores Strengths & Expansive Pipeline'
Dec 16, 2024 06:04AM IDEAYA Biosciences (IDYA) Announces Development Candidate Nomination of IDE251
Dec 10, 2024 06:01AM IDEAYA (IDYA) Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA®
Nov 5, 2024 06:22AM Leerink Partners Downgrades Ideaya Biosciences (IDYA) to Market Perform
Nov 4, 2024 06:17AM IDEAYA Biosciences (IDYA) Tops Q3 EPS by 2c
Oct 25, 2024 06:01AM IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 1 Expansion Data of IDE397
Oct 24, 2024 03:52AM UBS Starts Ideaya Biosciences (IDYA) at Buy
Oct 15, 2024 06:32AM Cantor Fitzgerald Starts Ideaya Biosciences (IDYA) at Overweight
Oct 15, 2024 05:54AM Goldman Sachs Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Oct 4, 2024 06:02AM IDEAYA Biosciences (IDYA) Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer
Sep 25, 2024 06:56AM Mizuho Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
Sep 24, 2024 06:14AM RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)
Sep 23, 2024 04:34PM Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Sep 23, 2024 03:48PM Ideaya Biosciences (IDYA) PT Raised to $48 at Goldman Sachs
Sep 23, 2024 03:45PM Ideaya Biosciences (IDYA) PT Lowered to $66 at Stifel
Sep 23, 2024 01:42PM BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Sep 23, 2024 06:07AM IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting
Sep 10, 2024 07:27AM Ideaya Biosciences (IDYA) PT Raised to $68 at Stifel
Aug 13, 2024 05:11AM Ideaya Biosciences (IDYA) PT Raised to $47 at Goldman Sachs
Aug 7, 2024 07:47AM Ideaya Biosciences (IDYA) PT Lowered to $53 at Oppenheimer
Jul 31, 2024 06:17AM IDEAYA Biosciences (IDYA) Enters Option and License Agreement with Biocytogen for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time
Jul 11, 2024 06:28AM Ideaya Biosciences (IDYA) PT Raised to $55 at Mizuho
Jul 11, 2024 06:19AM Ideaya Biosciences (IDYA) PT Raised to $61 at RBC Capital
Jul 10, 2024 05:21AM IDEAYA Biosciences (IDYA) Prices 7.23M Share Offering at $35/sh
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jul 9, 2024 04:09PM IDEAYA Biosciences (IDYA) Announces Proposed $200M Share and Warrant Offering
Jul 9, 2024 10:51AM Citi Reiterates Buy Rating on Ideaya Biosciences (IDYA)
Jul 8, 2024 03:45PM Ideaya Biosciences (IDYA) PT Raised to $62 at BTIG
Jul 8, 2024 12:38PM Ideaya Biosciences (IDYA) PT Raised to $60 at Oppenheimer
Jul 8, 2024 06:53AM Mizuho Starts Ideaya Biosciences (IDYA) at Outperform
Jun 27, 2024 06:14AM IDEAYA Biosciences (IDYA) Announces Resignation of Chief Legal Officer
Jun 24, 2024 06:02AM IDEAYA Biosciences (IDYA) Issues Clinical Program Updates for IDE397
View More Recent Stories View Older Stories